RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aurinia Pharmaceuticals Stock

Aurinia Pharmaceuticals Stocks 2024

Aurinia Pharmaceuticals Stocks

143.24 M

Ticker

AUPH

ISIN

CA05156V1022

WKN

A1W7D4

In 2024, Aurinia Pharmaceuticals had 143.24 M outstanding stocks, a 0% change from the 143.24 M stocks in the previous year.

The Aurinia Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e143.24
2028e143.24
2027e143.24
2026e143.24
2025e143.24
2024e143.24
2023143.24
2022141.9
2021129.4
2020118.5
201993
201884.8
201776.9
201635.3
201532.2
201429.2
20136.3
20123.6
20113.5
20102.8
20092.4
20082.1
20072.1
20061.7
20051.6
20041.5

Aurinia Pharmaceuticals shares outstanding

The number of shares was Aurinia Pharmaceuticals in 2023 — This indicates how many shares 143.236 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aurinia Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aurinia Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aurinia Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aurinia Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aurinia Pharmaceuticals Aktienanalyse

What does Aurinia Pharmaceuticals do?

Aurinia Pharmaceuticals Inc is a biopharmaceutical company that was founded in Canada in 1993. The company specializes in developing therapy options for autoimmune diseases, particularly the treatment of Lupus Nephritis, a condition where the immune system mistakenly attacks the body's own cells and damages the kidneys. Aurinia specializes in the field of biologic medications, which are based on proteins that naturally occur in the human body. These medications are used to modulate the immune system and "suppress" specific cells that trigger autoimmune diseases. Aurinia's main product is Voclosporin, an orally administered drug specifically developed for the treatment of Lupus Nephritis. Clinical trials have shown promising results, and Voclosporin received approval from the US FDA in 2020. Voclosporin is now successfully used in several countries worldwide. Aurinia also conducts research and development in other areas of autoimmune diseases. Another potential application is the treatment of Vogt-Koyanagi-Harada disease, a rare eye condition also attributed to autoimmune diseases. Aurinia's business model is based on developing new therapies that address the medical needs of patients with autoimmune diseases. The company focuses on close collaboration with medical professionals, patients and their families, as well as regulatory authorities. Aurinia has also formed partnerships with other companies and non-profit organizations to support its research and development and enhance access to its products in different countries. Aurinia's success relies on the extensive experience and expertise of its employees in biotechnological research, development and manufacturing of biologic medications, as well as its close partnerships with world-leading physicians in the field of autoimmune diseases. The company is committed to constantly improving the quality of its products and services to enhance patients' quality of life and effectively treat their disease. Overall, Aurinia Pharmaceuticals is a company dedicated to developing innovative therapies for autoimmune diseases, particularly for the treatment of Lupus Nephritis. The company strives to meet the medical needs of patients, their families, and medical professionals while also improving the entire ecosystem of medical care in this field. Aurinia's goal is to provide patients with better and more effective therapies and treatments to improve their health and well-being. Aurinia Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Aurinia Pharmaceuticals's Shares Outstanding

Aurinia Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Aurinia Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Aurinia Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Aurinia Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Aurinia Pharmaceuticals stock

How many stocks are there of Aurinia Pharmaceuticals?

The current number of stocks of Aurinia Pharmaceuticals is 143.24 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Aurinia Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Aurinia Pharmaceuticals evolved in recent years?

The number of shares of Aurinia Pharmaceuticals has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Aurinia Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Aurinia Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Aurinia Pharmaceuticals pay?

Over the past 12 months, Aurinia Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aurinia Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aurinia Pharmaceuticals?

The current dividend yield of Aurinia Pharmaceuticals is .

When does Aurinia Pharmaceuticals pay dividends?

Aurinia Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aurinia Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aurinia Pharmaceuticals located?

Aurinia Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aurinia Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aurinia Pharmaceuticals from 10/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/20/2024.

When did Aurinia Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/20/2024.

What was the dividend of Aurinia Pharmaceuticals in the year 2023?

In the year 2023, Aurinia Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aurinia Pharmaceuticals pay out the dividend?

The dividends of Aurinia Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Aurinia Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Aurinia Pharmaceuticals

Our stock analysis for Aurinia Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aurinia Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.